stockrowCelldex Therapeutics, Inc.
CLDX Healthcare Biotechnology
Celldex Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, down 78.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −10.6%
- Free cash flow
- −35.5%
Quarter to June 2026, against a year earlier
Follow CLDX
Alert me
Celldex Therapeutics, Inc. (CLDX) EV/FCF
As of 5 November 2026, Celldex Therapeutics, Inc. (CLDX) trades at a EV/FCF of −6.2×. Over the past ten years it has ranged from −42.7× (September 2021) to 0.9× (December 2018); the current reading is higher than 52% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −6.0× | — |
| FY2024 | −5.7× | — |
| FY2023 | −14.1× | — |
| FY2022 | −16.4× | — |
| FY2021 | −20.1× | — |
| FY2020 | −7.8× | — |
| FY2019 | 0.6× | (22.06%) |
| FY2018 | 0.8× | — |
| FY2017 | −2.4× | — |
| FY2016 | −1.6× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | −9.0× | — |
| Mar 2026 | −7.3× | — |
| Dec 2025 | −6.0× | — |
| Jun 2025 | −3.8× | — |
| 41 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| PVLA Palvella Therapeutics, Inc. compare | −62.4× |
| PHVS Pharvaris N.V. compare | −10.5× |
| IMNM Immunome, Inc. compare | −7.0× |
| CLDX Celldex Therapeutics, Inc. | −6.2× |
| VERA Vera Therapeutics, Inc. compare | −5.2× |
| BHVN Biohaven Ltd. compare | −4.5× |
| AUPH Aurinia Pharmaceuticals Inc compare | 9.7× |
| ADMA ADMA Biologics Inc compare | 25.2× |
| VCEL Vericel Corporation compare | 42.8× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on CLDX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement